Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria

Hypertension Research

Volumn 34, Issue 2, 2011, Pages 268-273

  Abe, Masanori ^a   Okada, Kazuyoshi ^a   Maruyama, Noriaki ^a   Matsumoto, Shiro ^a   Maruyama, Takashi ^a   Fujita, Takayuki ^a   Matsumoto, Koichi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

albuminuria; aldosterone; amlodipine; benidipine; chronic kidney disease

Indexed keywords

ALBUMIN; ALDOSTERONE; AMLODIPINE; BENIDIPINE; CREATININE; DIURETIC AGENT; POTASSIUM ION; RENIN; SODIUM ION;

AGED; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; POTASSIUM URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ALBUMINURIA; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEPHROSCLEROSIS; POTASSIUM; SEVERITY OF ILLNESS INDEX; SODIUM;

EID: 79751496804     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.221     Document Type: Article

References (36)

1. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-F93. (Pubitemid 11033923)
2. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777. (Pubitemid 26186610)
3. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin- aldosterone system in the progression of chronic kidney disease. Kidney Int 2005; 99: S57-S65.
4. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003; 83: 117-161. (Pubitemid 36459879)
5. Jones SW. Overview of voltage-dependent calcium channels. J Bioenerg Biomembr 1998; 30: 299-312. (Pubitemid 28436152)
6. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
7. Takeda Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralcorticoid receptor antagonists. Hypertens Res 2004; 27: 781-789. (Pubitemid 40309445)
8. Muller J. Aldosterone: the minority hormone of the adrenal cortex. Steroids 1995; 60: 2-9.
9. Imagawa K, Okayama S, Takaoka M, Kawata H, Nata N, Nakajima T, Horii M, Uemura S, Saito Y. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006; 47: 133-138. (Pubitemid 44378236)
10. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32: 270-275.
11. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 4-107.
12. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
13. Abbate M, Benigni A, Bertani T, Remuzzi G. Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999; 14: 304-312. (Pubitemid 29062783)
14. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G. Transforming growth factor-beta 1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 2179-2193. (Pubitemid 35434863)
15. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109: 1-8. (Pubitemid 30608730)
16. Dykeman-Sharpe J. Proteinuria, a modifiable risk factor: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). CANNT J 2003; 13: 34-38.
17. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
18. Raij L. Recommendations for the management of special populations: renal disease in diabetes. Am J Hypertens 2003; 16: 46S-49S. (Pubitemid 37449439)
19. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004; 24: 158-167. (Pubitemid 38387857)
20. Furukawa T, Nukada T, Miura R, Ooga K, Honda M, Watanabe S, Koganesawa S, Isshiki T. Differential blocking action of dihydropyridine Ca2+ antagonists on T-type Ca2+ channel (a1G) expressed in xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241-246. (Pubitemid 40328146)
21. Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, Kusaka H, Matsubara M. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584: 424-434.
22. Ertel SI, Ertel EA, Clozel J-P. T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther 1997; 11: 723-739. (Pubitemid 28056989)
23. Nitta Y, Yamamoto R, Yamaguchi Y, Katsuda S, Kaku B, Taguchi T, Takabatake S, Nakahama K, Yamagisi M. Impact of long-acting calcium channel blockers on the prognosis of patients with coronary artery disease with and without chronic kidney disease: a comparison of three drugs. J Int Med Res 2010; 38: 253-265.
24. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effects of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-1233.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl JMed 1999; 341: 709-717. (Pubitemid 29407370)
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
27. Vasan RS, Evans JC, Benjamin EJ, Levy D, Laeson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PWF. Relations of serum aldosterone to cardiac structure: gender-related difference in the Framingham Heart Study. Hypertension 2004; 43: 957-962. (Pubitemid 38579898)
28. Schunkert H, Hense HW, Muscholl M, Luchner A, Kurzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77: 24-31. (Pubitemid 27076910)
29. Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41.
30. Rossier MF, Lesouhaitier O, Perrier E, Bockhorn L, Chiappe A, Lalevee N. Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol 2003; 85: 383-388. (Pubitemid 37011114)
31. Laleve N, Rebsamen MC, Barrere-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 67: 216-224. (Pubitemid 40943614)
32. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 2007; 30: 691-697. (Pubitemid 47517102)
33. Okayama S, Imagawa K, Naya N, Iwama H, Somekawa S, Kawata H, Horii M, Nakajima T, Uemura S, Saito Y. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006; 29: 493-497. (Pubitemid 44363465)
34. Wagner C, Kramer BK, Hinder M, Kieninger M, Kurtz A. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br J Pharmacol 1998; 124: 579-585. (Pubitemid 28254516)
35. Karam H, Clozel JP, Bruneval P, Gonzalez MF, Menard J. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. Hypertension 1999; 34: 673-678. (Pubitemid 29496452)
36. Schweda F, Kurtz A. Cellular mechanism of renin release. Acta Physiol Scand 2004; 181: 383-390. (Pubitemid 39078833)